Anti-Human CD28 (CD28.2)
CD28 Monoclonal Antibody for FC
Host / Isotype
Mouse / IgG1, kappa
Reactivity
Human and More (1)
Applications
FC and More (2)
Conjugate
Unconjugated
CloneNo.
CD28.2
验证数据展示
经过测试的应用
Positive FC detected in | human PBMCs |
推荐稀释比
Application | Dilution |
---|---|
This reagent has been tested for flow cytometric analysis. It is recommended that this reagent should be titrated in each testing system to obtain optimal results. | |
Sample-dependent, Check data in validation data gallery. |
发表文章中的应用
IHC | See 1 publications below |
产品信息
65099-1-Ig targets CD28 in FC, IHC, Cell treatment applications and shows reactivity with Human samples.
Tested Applications | FC Application Description |
Cited Applications | IHC, Cell treatment |
Tested Reactivity | Human |
Cited Reactivity | human |
Immunogen | N/A 种属同源性预测 |
Host / Isotype | Mouse / IgG1, kappa |
Class | Monoclonal |
Type | Antibody |
Full Name | CD28 molecule |
Synonyms | CD28, CD28 molecule, Tp44 |
Calculated Molecular Weight | 220 aa, 25 kDa |
GenBank Accession Number | BC093698 |
Gene Symbol | CD28 |
Gene ID (NCBI) | 940 |
ENSEMBL Gene ID | ENSG00000178562 |
RRID | AB_2918401 |
Conjugate | Unconjugated |
Form | Liquid |
Purification Method | Affinity purification |
UNIPROT ID | P10747 |
Storage Buffer | PBS with 0.09% sodium azide. |
Storage Conditions | Store at 2-8°C. Stable for one year after shipment. |
背景介绍
实验方案
Product Specific Protocols | |
---|---|
FC protocol for CD28 antibody 65099-1-Ig | Download protocol |
Standard Protocols | |
---|---|
Click here to view our Standard Protocols |
发表文章
Species | Application | Title |
---|---|---|
Cancer Cell Int Comprehensive analysis of prognostic immune-related genes and drug sensitivity in cervical cancer. | ||
J Transl Med Scoring model based on the signature of non-m6A-related neoantigen-coding lncRNAs assists in immune microenvironment analysis and TCR-neoantigen pair selection in gliomas | ||
Aging (Albany NY) An integrated bioinformatic investigation of focal adhesion-related genes in glioma followed by preliminary validation of COL1A2 in tumorigenesis |